ATRA
NASDAQ · Biotechnology
Atara Biotherapeutics Inc
$7.93
-0.30 (-3.65%)
Financial Highlights (FY 2026)
Revenue
96.41M
Net Income
26.09M
Gross Margin
82.4%
Profit Margin
27.1%
Rev Growth
+23.9%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.4% | 82.4% | 58.2% | 58.2% |
| Operating Margin | 29.7% | 26.7% | -3.7% | -3.7% |
| Profit Margin | 27.1% | 25.7% | -2.9% | -3.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 96.41M | 77.84M | 4.60M | 4.74M |
| Gross Profit | 79.48M | 64.17M | 2.67M | 2.76M |
| Operating Income | 28.62M | 20.80M | -170,760 | -175,722 |
| Net Income | 26.09M | 18.96M | -132,709 | -155,737 |
| Gross Margin | 82.4% | 82.4% | 58.2% | 58.2% |
| Operating Margin | 29.7% | 26.7% | -3.7% | -3.7% |
| Profit Margin | 27.1% | 25.7% | -2.9% | -3.3% |
| Rev Growth | +23.9% | +23.9% | -8.7% | +11.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.37M | 1.37M | 15.40M | 16.39M |
| Total Equity | 38.58M | 38.58M | 18.11M | 18.20M |
| D/E Ratio | 0.04 | 0.04 | 0.85 | 0.90 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 30.32M | 23.26M | -214,542 | -195,381 |
| Free Cash Flow | — | — | -85,981 | -141,773 |